Merck & Co., Inc. logo
Merck & Co., Inc. (MRK)
Compare

Merck & Co., Inc. (MRK) Enterprise Value (EV): $299.33B

The enterprise value (EV) for Merck & Co., Inc. (MRK) is $299.33B as of Wednesday, June 10, 2026.

MRK Enterprise Value (EV) Metrics

ENTERPRISE VALUE (EV)

$299.33B

MRK Competitors' Enterprise Value (EV)

NAMEMARKET CAPENTERPRISE VALUE (EV)
Merck & Co., Inc. (MRK)$299.33B
UnitedHealth Group Incorporated (UNH)$368.44B$354.42B
AbbVie Inc. (ABBV)$399.54B$470.64B
Amgen Inc. (AMGN)$183.75B$221.57B
Thermo Fisher Scientific Inc. (TMO)$179.45B$248.87B
Abbott Laboratories (ABT)$154.66B$225.43B
Gilead Sciences, Inc. (GILD)$151.21B$169.72B
Intuitive Surgical, Inc. (ISRG)$146.44B$199.07B
Pfizer Inc. (PFE)$146.36B$207.77B
Danaher Corporation (DHR)$130.25B$175.72B

Enterprise Value Calculation

Market Cap

$293.02B

+

Total Debt

$49.63B

Cash

$14.56B

=

Enterprise Value

$299.33B

EV-Based Valuation Multiples

Why use EV instead of Market Cap?

  • EV accounts for debt - an acquirer must pay or assume it
  • EV deducts cash - the acquirer effectively receives it
  • EV enables fair comparison of companies with different capital structures
  • EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral

Merck & Co., Inc. Enterprise Value (EV) Formula & Definition

Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Merck & Co., Inc. Enterprise Value (EV) FAQ

What is the enterprise value (EV) for Merck & Co., Inc. (MRK)?
The enterprise value (EV) for MRK stock is $299.33B.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Rahway, NJ
73,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Davis